BC
INFI

Broadfin Capital’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Broadfin Capital’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,500
Closed -$495K – 79
2014
Q3 		$495K Hold
1,500
– – 0.05% 71
2014
Q2 		$443K Buy
+1,500
New +$15.6K 0.04% 68

Other funds holding INFI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Broadfin Capital's INFI Position: Q1 2015 in Review

Broadfin Capital sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2015, closing a stake of 450,000 shares — an estimated $7.6M sold.

Broadfin Capital first reported a position in INFI in Q2 2013 and held it in 7 quarters. The position peaked at $18.3M in Q2 2014. 141 funds tracked by Wall St. Rank hold INFI as of Q1 2015.

  • Broadfin Capital reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Broadfin Capital sold 450,000 Infinity Pharmaceuticals, Inc. shares in Q1 2015, an estimated $7.6M.
  • Broadfin Capital first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 7 quarters.
  • Broadfin Capital's Infinity Pharmaceuticals, Inc. position peaked at $18.3M in Q2 2014.
  • 141 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2015.

Based on Broadfin Capital's 13F filing for Q1 2015, filed 15 May 2015.